Status:
UNKNOWN
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
Lead Sponsor:
Bioimmunate
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Brief Summary
Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing...
Eligibility Criteria
Inclusion
- Patients with diagnosis of MS according to the revised criteria of McDonald or healthy volunteers
- Ability to provide written informed consent.
Exclusion
- \- Active malignant disease
Key Trial Info
Start Date :
April 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03486665
Start Date
April 24 2018
End Date
March 1 2020
Last Update
July 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Center
Jerusalem, Israel